What is Tirzepatide?
Tirzepatide is a dual agonist peptide that simultaneously targets two incretin receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Originally developed for type 2 diabetes management, its profound effects on body weight and metabolic health have made it one of the most studied compounds in contemporary metabolic research. It is administered as a once-weekly subcutaneous injection.
Mechanism of Action
Tirzepatide's dual receptor activity produces complementary and synergistic metabolic effects:
- GLP-1 Agonism: Stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite via central nervous system pathways.
- GIP Agonism: Enhances insulin sensitivity in peripheral tissues, promotes adipocyte lipid metabolism, and may potentiate GLP-1's appetite-suppressing effects. GIP receptor activation also appears to reduce the nausea commonly associated with GLP-1 monotherapy, improving tolerability.
Together, these mechanisms produce superior glycaemic control and weight reduction compared to GLP-1 agonists alone.
Key Research Findings
- Weight Reduction: The SURMOUNT-1 trial demonstrated mean body weight reductions of up to 22.5% at the highest dose (15 mg) over 72 weeks in non-diabetic participants with obesity.
- Glycaemic Control: SURPASS clinical trials showed HbA1c reductions of up to 2.58% — among the most significant reductions observed in type 2 diabetes pharmacotherapy.
- Cardiovascular Benefits: Reductions in systolic blood pressure, triglycerides, and LDL cholesterol, alongside improvements in HDL cholesterol.
- Liver Health: Significant reductions in hepatic fat content, with implications for NAFLD and NASH management.
Comparison with Retatrutide
While Tirzepatide targets GLP-1 and GIP receptors, Retatrutide adds glucagon receptor agonism as a third mechanism, further increasing energy expenditure and hepatic fat oxidation. Both compounds represent the leading edge of metabolic peptide research, with Tirzepatide having the more extensive clinical trial dataset to date.
Important Notes
Tirzepatide is sold strictly for research purposes. All information provided is based on published clinical trial data and preclinical research. This content is not intended as medical advice. Consult a qualified healthcare professional before use.